Last reviewed · How we verify
PIKA COVID-19 vaccine
At a glance
| Generic name | PIKA COVID-19 vaccine |
|---|---|
| Sponsor | Yisheng Biopharma (Singapore) Pte. Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose. (PHASE2, PHASE3)
- A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PIKA COVID-19 vaccine CI brief — competitive landscape report
- PIKA COVID-19 vaccine updates RSS · CI watch RSS
- Yisheng Biopharma (Singapore) Pte. Ltd. portfolio CI